Patent · US Active

Combination therapy with an anti-CD25 antibody-drug conjugate

US11596696B2 · kind B2 · utility

1Cited by

31References

13Claims

0Family size

Assignees

ADC THERAPEUTICS SA · CH
MedImmune Limited · US

Inventors

Patricius Hendrikus Cornelis Van Berkel · Épalinges, CH
Lisa Skelton · Épalinges, CH
Francesca ZAMMARCHI · Épalinges, CH
Jay Marshall Feingold · New Providence, US
Jens Wuerthner · Steinen, DE
John Hartley · London, GB

Key dates

Filing date	Apr 20, 2018
Grant date	Mar 7, 2023
Priority date	—
Expiry date	Aug 29, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.